TBP Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

TBP Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	$847K	Hold	1,875	–	–	0.53%	34
2014 Q4	$769K	Hold	1,875	–	–	0.5%	32
2014 Q3	$676K	Hold	1,875	–	–	0.39%	39
2014 Q2	$530K	Hold	1,875	–	–	0.31%	39
2014 Q1	$563K	Hold	1,875	–	–	0.35%	39
2013 Q4	$516K	Hold	1,875	–	–	0.33%	40
2013 Q3	$587K	Hold	1,875	–	–	0.41%	39
2013 Q2	$422K	Buy	+1,875	New	+$437K	0.29%	46

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TBP Advisors's REGN Position: Q1 2015 in Review

TBP Advisors held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2015 at 1,875 shares worth $847K. The position accounts for 0.53% of the portfolio, ranked #34.

TBP Advisors first reported a position in REGN in Q2 2013 and has held it in 8 quarters since. 508 funds tracked by Wall St. Rank hold REGN as of Q1 2015.

TBP Advisors held 1,875 shares of Regeneron Pharmaceuticals worth $847K as of Q1 2015.
TBP Advisors left its Regeneron Pharmaceuticals share count unchanged in Q1 2015.
Regeneron Pharmaceuticals made up 0.53% of TBP Advisors's portfolio in Q1 2015, its #34 holding.
TBP Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 8 quarters since.
508 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2015.

Based on TBP Advisors's 13F filing for Q1 2015, filed 17 Apr 2015.